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Summary--Opioid agonists of the mu, kappa and delta types stimulated low-Km guanosine triphos- 
phatase (GTPase) in membranes, from the brain of the rat by up to 34%, with potencies the rank order 
of which corresponded to the respective binding affinities to opioid receptor. In general, kappa ligands 
stimulated GTPase to a lesser degree than mu or delta opiates. The coupling of a given type of opioid 
receptor to GTPase was resolved by direct or protective alkylation of the other receptors. Treatment of 
the membranes with I-funaltrexamine abolished the stimulation of GTPase by sufentanil and levorphanol 
(mu), but not by bremazocine (kappa) or DSLET (delta). On the other hand, prior incubation with 
Superfit, an alkylating agent with selectivity for the delta opioid receptor, specifically eliminated the effect 
of DSLET. Partial alkylation by increasing concentrations of Superfit gradually reduced the extent of 
stimulation of GTPase by DSLET. The successive treatment of membranes with Superfit and /?-funaltrex- 
amine blocked the actions of DSLET, sufentanil and levorphanol, but had no effect on the stimulation 
of the GTPase by bremazocine. Selective coupling of an opioid receptor to GTPase was also obtained 
after incubation of membranes with B-chlornaltrexamine in the presence of protective concentrations of 
mu, kappa or delta opioid ligands. Alkylation resolved the coupling of the non-selective opiate etorphine: 
the sum of stimulation of GTPase in the receptor-selective membranes equalled maximal stimulation of 
enzyme in untreated membranes. Naloxone blocked the stimulation of GTPase by mu, kappa or delta 
agonists, but ICI-174,864 specifically inhibited the effect of DSLET. The results describe the use of 
receptor-selective membranes from brain to characterize the coupling of multiple opioid receptors to 
high-affinity GTPase, the inhibitory binding protein for GTP of the adenylate cyclase complex. 
Key words: multiple opioid receptors, opioid receptor-effector coupling, GTP binding proteins, receptor 
alkylation, brain membranes, rat brain. 
The binding of agonists to opioid receptors ap- 
pears to be translated into at least two different, 
although not necessarily independent, alterations in 
cell function: an inhibition of the neuronal action 
potential discharge (Bixby and Spitzer, 1983; 
Williams and North, 1984) and the inhibition of 
adenylate cyclase. The interaction of opiates with 
adenylate cyclase has been described in NG108-15 
neuroblastoma x glioma hybrids (Sharma, Nirenberg 
and Klee, 1975), slices of brain (Barchfeld, Maassen 
and Medzihradsky, 1982) and membranes from brain 
(Law, Wu, Koehler and Loh, 1981). In addition to 
causing inhibition of adenylate cyclase, opiates stim- 
ulated the activity of a low-Km guanosine triph- 
osphatase (GTPase) in membranes from NG108-15 
cells (Koski and Klee, 1981) and rat brain (Barchfeld 
and Medzihradsky, 1984). In NG108-15 hybrid cells 
pertussis toxin inhibited the stimulation of GTPase 
by opiates, thus suggesting the involvement of the 
binding protein for GTP (Hildebrandt, Sekura, Cod- 
ina, Iyenger, Manclark and Birnbaumer, 1983) in the 
coupling of opioid receptors to adenylate cyclase 
(Burns, Hewlett, Moss and Vaughan, 1983; Kurose, 
Katada, Amaro and Ui, 1983). Considering the re- 
quirement of the latter process for GTP (Blume, 
Lichtshtein and Boone, 1979), the opiate-sensitive 
GTPase is causally linked to the mechanism of opioid 
receptor-effector interaction: the hydrolysis of GTP 
uncouples the receptor-effector complex. The opioid 
receptor mediated stimulation of low-Km GTPase in 
membranes from brain has been described (Barchfeld 
and Medzihradsky, 1984). The general characteristics 
by which opiates stimulated GTPase corresponded to 
those of their inhibition of adenylate cyclase in 
cellular preparations from the brain of the rat (Bar- 
chfeld et al., 1982). Recently, differences in the degree 
and potency by which ligands of the multiple opioid 
receptors stimulated GTPase in brain were reported 
(Clark and Medzihradsky, 1985; Clark, Levenson 
and Medzihradsky, 1986). In the present work, the 
stimulation of GTPase by mu, kappa and delta 
opiates in membranes from brain, alkylated to pro- 
vide specificity toward a given type of opioid recep- 
tor, has been resolved and characterised. 
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METHODS 
Most of the opiates, including @-FNA 
@-funaltrexamine) and Superfit (cis-( t_ )-3- 
methylfentanylisothiocyanate) (Clark et al., 1986; 
Smith, Jacobson, Burke, Rice and Woods, 19SS), 
used in this study were obtained through the Narcotic 
Drug and Opioid Peptide Basic Research Center, 
The University of Michigan. UM 1071 R ([IR,5R,9R, 
2”R]-5,9-dimethyl-2’-hydroxy-2-tetrahydrofurfuryl- 
6,7_benzomorphan is a benzomorphan derivative 
with kappa agonist activity (Medzihradsky, Dahl- 
Strom, Woods, Fischel and Mitsos, 1984). 
ICI 171,864 (N,N-diallyl-Tyr-Aib-Aib-Phe-Leu-OH; 
Aib: ~-aminoisobutyric acid) is a highly selective 
antagonist at the delta opioid receptor (Cotton, 
Giles, Miller, Shaw and Timms, 1984); #?-CNA 
(~-chlornaltrexamine) was purchased from Research 
Biochemicals Inc., Wayland, Massachusetts, U.S.A. 
and DSLET ([D-Ser*,leu’]enkephalin-Thr6) was ob- 
tained from Cambridge Research Biochemicals Ltd, 
Atlantic Beach, New York, U.S.A. Gamma-[32P]GTP 
(20 Ci/mmol) was obtained from Amersham Cor- 
poration, Arlington Heights, Illinois, U.S.A. The 
biochemicals used in the assay for GTPase, including 
the stable adenosine and guanosine derivatives 
APP(NH)P (&y-imidoadenosine-S-triphosphate) 
and Gpp(NH)p @,y-imidoguanosine-5’-triphos- 
phate), were from Sigma Chemical Co., St Louis, 
Missouri, U.S.A. 
isolation of membranes 
Parts of this procedure have been published pre- 
viously (Fischel and Med~hradsky, 1981). Male, 
Sprague-Dawley rats weighing 200g were decapi- 
tated and the brains excised at 4°C. The cerebrum 
was dissected, washed in Tri-HCl (pH 7.4), blotted 
and cleaned of adhering blood vessels. The weighed 
tissue was disrupted for 60 set in 100 vol of ice-cold 
50 mM Tris-HC1 (pH 7.4), using a Polytron homoge- 
nizer (Model PTlO, Brinkman Instruments Inc., 
Westbury, New York) at the power output 6.5. The 
homogenate was centrifuged at 20,000 x g for I5 min 
in the cold. The pellet obtained was suspended with 
the original amount of buffer, using a Dounce all- 
glass homogenizer. Aliquots of this suspension, 
sufficient for experiments on one given day, were 
frozen at -70°C. Prior to use, the suspension was 
quickly thawed in a water bath and briefly dispersed 
in a Dounce homogenizer. The concentration of 
protein in the latter preparation was approximately 
0.5 mg/ml. 
Receptor alkylation 
For the direct alkylation, the suspension of cere- 
bral membranes in Tris-HCl (pH 7.4), with a con- 
centration of protein of 0.35 mg/ml, was incubated 
with 100 /IM Superfit for 40 min at 25°C in a shaking 
water bath. After centrifugation at 20,000 x g for 
15 min at 2°C the pellet was suspended in a Dounce 
homogenizer with the original volume of 50mM 
Tri-HCl (pH7.4). This suspension was then incu- 
bated with 200 FM ~-funaltrexamine for 40 min at 
25°C in a shaking water bath. After a five-fold 
dilution with Tri-HCl (pH 7.4), the suspension was 
centrifuged at 20,000 x g for 15 min at 4°C. The 
pellet was suspended in 5 original volumes of the Tris 
buffer and centrifuged as described above. The wash- 
ing procedure was repeated once more and the pellet 
suspended in the original volume of Tris-HCl 
(pH 7.4). The alkylated membranes were either used 
fresh or frozen in aliquots at -70°C. Freezing and 
storage had no detectable effects on the results. 
For the protective alkylation, the suspension of 
cerebral membranes in Tris-HCl buffer (pH 7.4), 
with a protein concentration of 0.3.5mg/ml, was 
incubated with 800 p M levorphanol or bremazocine, 
or 400 PM DSLET for 5 min at 25°C. After NaCl 
and ~~hlornaltrexamine were added to a final con- 
centration of 100 mM and 25 PM, respectively, the 
suspension was incubated for 40 min at 25°C and 
then centrifuged at 20,000 x g for 15 min at 2°C. The 
pellet was suspended in a Dounce homogenizer with 
5 original volumes of the Tris buffer, and again 
centrifuged as described above. The washing pro- 
cedure was repeated once more, and the final pellet 
was suspended in the original volume of Tris buffer. 
An additional washing step had no effect on the 
parameters of stimulation of GTPase. Aliquots of the 
membrane suspension were frozen at -70°C. 
Assay of GTPase 
The assay represented a modification of the pre- 
viously published procedure (Barchfeld and Med- 
zihradsky, 1984) and was based on the method of 
Cassel and Selinger ( 1976). In a final volume of 100 I( 1 
the assay medium (in 4ml polypropylene tubes) 
contained: 0.5 PM [“P]GTP (0.05-0.1 PC per tube), 
2-4 fig membrane protein, 12.5 mM Tris-HCI (pH 
7.5), 120 mM NaCl, 5 mM MgCl,, 0.1 mM ethylene 
diamine tetra ammonium (EDTA), 2mM dithio- 
threitol, 1 mM App(NH)p, 1 mM ouabain, 0.5 mM 
adenosine triphosphate (ATP), 10 mM creatine phos- 
phate and 5 units creatine kinase. In experiments with 
dynorphin, the tubes were initially rinsed with 1% 
bovine serum albumin in 50 mM Tris-HCl (pH 7.4). 
The opioid ligands were added in IO-20 ~1 of aque- 
ous solutions. In separate tubes, the reaction mixture 
also contained 50 PM GTP to measure the activity of 
the opiate-insensitive, high-Km GTPase. The cpm’s 
obtained in the presence of 50 PM GTP were sub- 
tracted from the cpm’s for total enzyme activity to 
yield a cpm value representing the activity of the 
opiate-sensitive, low-Km GTPase. 
After the addition of radiolabelled GTP, the sam- 
ples were incubated for 10 min at 37°C and 1 ml of 
25% activated charcoal (suspended at pH 2.3 in 
phosphoric acid) was added. After standing for 
30min in ice, the tubes were centrifuged at 5000 x g 
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for 15 min and 300 ~1 of the supernatant was subjec- 
ted to liquid scintillation counting. The following 
controls were routinely included in each assay: basal 
activity of GTPase in the absence of opiates, hydro- 
lysis of GTP in the absence of membranes and 
hydrolysis of GTP prior to sample incubation. 
Determination of protein 
The method of Lowry, Rosebrough, Farr and 
Randall (1951) was used with bovine serum albumin 
as standard. 
Statistical evaluation of the data 
The stimulation of low-Km GTPase in brain was 
characterized by the parameters KS and S,,,,,. The 
KS, the ligand concentration producing half-maximal 
stimulation of basal enzyme activity, was determined 
by linear regression from plots relating stimulation 
of GTPase in probits to the log of ligand concen- 
tration at 4-5 data points. The S,,,,,, the maximal 
stimulation of basal low-Km GTPase, was obtained 
with gradually increasing concentrations of ligand as 
a well-defined upper limit of enzyme activity. Opioid 
agonists, present at concentrations greater than that 
yielding S,,,, , progressively inhibited stimulation of 
GTPase. The potency of antagonists in inhibiting the 
stimulation of GTPase was expressed as EC, and 
was determined from log-probit plots, as described 
above. The values for KS, S,,,,, and EC,, were 
expressed as means f standard deviations, based 
upon 3-6 experiments. The significance of the data 
was tested by a one-way analysis of variance that 
compared effects of ligands with control, or for a 
given ligand, alkylated membranes with no treat- 
ment. The results were accepted as different from 
control if the computed statistic exceeded the corre- 
sponding theoretical statistic at the 5% level of signi- 
ficance. The comparison of the means was carried out 
by the Scheffe test (Scheffe, 1953). 
RESULTS 
The rationale for the composition of the GTPase 
assay medium is described in the original publication 
by Cassel and Selinger (1976). The present authors 
have confirmed 0.5 PM and 50 pMGTP, described 
by Koski and Klee (1981), as the optimal concen- 
trations to measure the opiate-sensitive and -in- 
sensitive activities of GTPase, respectively. Pro- 
cedural details of the method described (Koski and 
Klee, 1981) were modified in order to improve pre- 
cision, an important aspect considering the limited 
range of stimulation of the enzyme (Fig. 1). Initially, 
the linearity of the enzyme assay with time and 
protein was established. In addition, it was shown 
that the basal rate of activity of GTPase in mem- 
branes of brain was not altered by the alkylations 
with /3-funaltrexamine and Superfit. The variability 
of the basal activity of GTPase (Table 1) reflected the 
contribution of several preparations of membranes 
used in this study. Compared to mu opiates, stimu- 
lation of low-Km GTPase by kappa ligands was 
considerably less (Fig. I). The delta opiate DSLET 
stimulated GTPase to an extent similar to, or greater 
than that of mu ligands (Fig. 3). The rank order of 
the KS values for stimulation of the enzyme (Fig. I), 
correlated with the receptor binding affinities of the 
respective opiates (Medzihradsky et al., 1984). 




Stimulation of GTPase activity 
s s s max 
Experimental conditions mg protein min (p%) max W) (z$ max (“/) W) 
Levorphanol Bremarocine DSLET 
No treatment 75 f 10.4 9.0 f 2.6 24 f 4.0 17 f 3.5 I3 f 5.5 6.6 f 0.6 25 + 5.3 
A. DIRECT ALKYLATION 
,%FNA, 200 pM 69i 14 0 6.9 f 0.9* 6.5 f 1.3* 18 f 6.l* 27 k 8.3 
Superfit, 100 pM 58k 17 14 f 5.5 8.7 * 3.8* 12k4.9 12 k 3.6 0 
P-FNA + Superfit 68 f 9 0 12k4.4 I9 ? 6.7 0 
Dynorphin 
b-FNA + Supertit 3.6 IO 
B. PROTECTIVE ALKYLATION 
Sufentanil Bremozocine DSLET 
No treatment (see above) 1.9 f 0.6 18 f 3.1 (see above) (see above) 
p-CNA, 25 pM 69 + 21 0 0 0 
/?-CNA + sufentanil 83 f 24 5.2 f 3.0 22*2.0 - 0 0 
fl-CNA + DSLET 73 * 22 0 0 6.0 f 0.6 30 f 7.0 
For direct alkylation, cerebral membranes of the rat were incubated with IOOpM Superfit or 200pM p-FNA for 40min at 25°C and 
washed as described under Methods. If treated with both alkylators, incubation with Supertit was followed by washing and treatment 
with B-FNA. For protective alkylation, the membranes were incubated with 800 pM sufentanil or 400 PM DSLET for 5 min at room 
temperature. Then N&l and /I-CNA were added to give final concentrations of 100 PM and 25 pM, respectively. After incubation 
for 40 min at 25”C, the membranes were centrifuged and washed as described. The concentration for half-maximal stimulation (Kd, 
and maximal stimulation (S,,,) of the basal activity is shown for the opioid agonists levorphanol and sufentanil (mu), bremazocine 
and dynorphin-(l-13) (kappa) and DSLET (delta), Shown are mean values and standard deviations obtained in 3-5 experiments carried 
out in triplicate (the experiment with dynorphin was carried out once). The significance of the data relative to the control values (no 
treatment) was examined by analysis of variance and a comparison test as described under Methods. The statistically different means 
are indicated by an asterisk. 
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Fig. I. Stimulation of the activity of GTPase by mu and kappa opiates. The activity of GTPase in cerebral 
membranes in the presence of various concentrations of a given opiate was measured as described under 
Methods. Shown are (i) the concentrations of opiates which produced half-maximal stimulation of 
GTPase (&, open bars) and (ii) the maximal stimulation of the basal rate by the opiates (S_ , closed 
bars). Represented in (A) are the mu opiates sufentanil (SUF), levorphanol (LEV), morphine (MOR) and 
ketobemidone (KETOB). The broken bar for KETOB reflects a KS value of 51 FM. (B) contains results 
obtained with the kappa opiates bremazocine (BREM), UM 1071R (1071R), ethylketocyclazocine (EKC) 
and ketazocine (KETAZ). The broken bar for KETAZ reflects a KS value of 240 PM. Shown are the 
means of data obtained in 3--.5 experiments, each run in triplicate or quadruplicate. Typical standard 
deviations were &8% for Ks and &6% for S,,,,, The statistical analysis of the data, carried out as 
described under Methods, showed that all S,, values in (A) were significantly different from the basal 
activity of GTPase (mean value 75.2 + 10.4 pmol Pi/mg protein. min). The S,,, values in (B) did not meet 
the 5% level of significance. 
Whereas naloxone blocked the stimulation of GTP- 
ase by mu, kappa and delta opiates, the delta- 
selective opioid antagonist ICI 174,864 specifically 
inhibited the effect of DSLET (Fig. 2). 
In order to resolve the stimulation of GTPase in 
brain by different types of opioid agonists, site- 
selective alkylations were carried out. Direct al- 
kylation was accomplished with the mu- and delta- 
selective irreversible ligands /3-funaltrexamine (Ward, 
Portoghese and Takemori, 1982) and Superfit (Smith 
et al., 1985; Clark et al., 1986; Clark and Me- 
dzihradsky, 1986). In addition, alkylation with the 
nonspecific ligand fl-chlornaltrexamine (Ward et al., 
1982), in the presence of protective concentrations of 
selective mu, kappa and delta opiates, respectively, 
was implemented. The selective opiates included suf- 
entanil and levorphanol as mu, bremazocine as 
kappa, and DSLET as delta ligands. Initial alkylation 
with /Y?-funaltrexamine or Superfit abolished the stim- 
ulation of GTPase by mu agonists and delta agonists, 
respectively (Table 1). In addition, alkylation with 
both p-funaltrexamine and Superfit conveyed 
specificity to the kappa opioid receptor, as demon- 
strated by the exclusive stimulation of GTPase by 
kappa opiates. Selective stimulation of GTPase by 
mu, kappa or delta opiates was also obtained in 
membranes treated with /?-chlornaltrexamine in the 
presence of appropriate ligands (Table 1). The con- 
centration of these opiates employed was optimal for 
protection of receptors, as reflected in the activation 
of GTPase considering both KS and S,,,,,. Smaller 
concentrations than those listed resulted in decreased 
values for S,,, and/or increased Ks, with the latter 
parameter responding first. As expected, alkylation of 
membranes with P-chlornaltrexamine alone abol- 
ished stimulation of GTPase by any opiate. 
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Fig. 2. Inhibition of the stimulation of GTPase by opioid 
antagonists. The activity of GTPase in untreated cerebral 
membranes was assayed in the presence of 6OpM le- 
vorphanol (A), bremazocine (0) or DSLET (0) and 
different concentrations of naloxone (A) or ICI 174,864 (B). 
The plots show the probit transformation of percentage 
inhibition as a function of the concentration of the antago- 
nist. The correlation coefficients (r2) for the lines were 
0.95-0.96. The EC,‘s @M) of naloxone in inhibiting the 
stimulation of GTPase by ievorphanol, bremazocine and 
DSLET were 27 f 6, 7.6 f 1.8 and 1.1 f 0.1, respectively. 
The ICI 174,864 inhibited the stimulation of G%Pase Gy 
DSLET with an EC, of 2.0 + 0.4 FM, but did not block the 
stimulation induced by levorphanol or bremazocine. Shown 
are mean values of 3 experiments run in triplicate. 
Alkylation with gradually increasing concen- 
trations of Superfit, resulted in proportionally de- 
creased stimulation of low-Km GTPase (Fig. 3). 
Whereas 10 PM Superfit had no effect, pretreatment 
with 100pM of the alkylator abolished the stimu- 
lation of enzymatic activity. At all concentrations of 
Superfit used, the alkylation approximately doubled 
the co~esponding ZC, value for stimulation of 
GTPase by DSLET (Fig. 3). Such impairment in 
the potency of opiates to stimulate GTPase after 
alkylation was observed in membranes alkylated by 
the direct approach, but not after protective alkyla- 
tions using /3-chlornaltrexamine (Table 1). 
The coupling of multiple opioid receptors to 
GTPase in brain was resolved into components by 
the effect of etorphine, a nonselective opioid agonist, 
after selective alkylation of receptors (Fig. 4). Stimu- 
lation of GTPase induced by the binding of etorphine 
to the mu and delta receptor was blocked by initial 
alkylation with B-funaltrexamine and Supetfit, re- 
spectively. Each of the two alkylations decreased S,, 
by approximately 10%. The stimulation of GTPase 
due to occupancy by etorphine of the kappa receptor 
was dete~ined in membranes alkylated by both 
~-funaltrexamine and Superfit, although again the 
significance of the kappa effect was difficult to estab- 
lish. Nonetheless, the sum of the individual com- 
ponents of the stimulation of GTPase in response to 
the occupancy of the mu, kappa and delta receptors 
equalled in extent the stimulation by etorphine in 
non-alkylated membranes (Fig. 4). 
DISCUSSION 
Based on its characteristics, the stimulation of high 
affinity GTPase by opiates represents a functional 
consequence of occupancy of opioid receptors and 
reflects the interaction of receptors with the in- 
hibitory guanine nucleotide-binding protein (Ni) 
(Milligan and Klee, 1985). The direct involvement of 
Ni in the function of opiates during their acute 
(Wuster, Costa, Aktories and Jakobs, 1984) and 
chronic (Lux and Schulz, 1985) presence has been 
demonstrated. As shown previously, stimulation of 
GTPase in mammalian brain was stereospecific, lim- 
ited to opioid agonists and inhibited by antagonists 
(Barchfeld and Medzihradsky, 1984). Contributing to 
the relatively large concentrations of opiates at which 
stimula~on of the enzyme occurred (low FM range) 
was the presence in the assay medium of sodium and 
GTP which reduced the binding of the agonist to the 
opioid receptor (Blume, 1978). Accordingly, antago- 
nists exhibited greater potencies in blocking the stim- 
ulation of GTPase than did agonists in causing it 
(Fig. 2). The relatively large effective concentrations 
of the opiates can also reflect impaired coupling of 
the opioid receptor to the effector in isolated brain 
membranes, as compared to intact cellular prepara- 
tions (Barchfeld et al., 1982; Katz and Catravas, 
1977). 
In the present work, opiates of all three types 
stimulated GTPase, although the effect of kappa 
opiates was of marginal statistical significance. The 
lesser extent of enzyme stimulation by kappa, relative 
to mu and delta, ligands corresponds to the low 
sensitivity of their receptor binding toward the regu- 
lation by GTP and Gpp(NH)p (Mack, Lee and 
Weyhenmeyer, 1985; Clark et al., 1986). Further- 
more, the additional coupling of the kappa opioid 
receptor to an effector system, other than the Ni- 
adenylate cyclase complex, e.g. an ion channel 
(Pfaffinger, Martin, Hunter, Nathanson and Hille, 
1985), cannot be ruled out. It has recently been 
shown that kappa opiates significantly stimulated 
GTPase in membranes from the cerebellum of the 
guinea-pig, a tissue predominantly containing kappa 
opioid receptors (Clark et al., 1986). 
Stimulation of GTPase due to ligand occupancy of 
individual types of opioid receptors was resolved by 
site-specific alkylations with irreversible ligands, The 
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Fig. 3. Effect of partial receptor alkylation on stimulation of GTPase. Cerebral membranes were treated 
with the indicated concentrations of Superfit as described under Methods. Control membranes were 
incubated without the alkylator. Subsequently, the activity of GTPase was assayed: (A) shows the KS 
values (open bars) and S,, (closed bars). Shown are mean values of 3 experiments carried out in triplicate. 
The KS values after treatment with 25, 75 and IO0 PM Super& were significantly different from those of 
the unaikylated control (see Methods). The S,,, was si~ific~tly different from control in membrane 
treated with 75 and 100 PM of Superfit. (B) shows the correlation between stimulation of GTPase and 
the concentration of Superfit. The correlation coefficient of the line (r’) was 0.98, as determined by 
regression analysis. In membranes treated with 100 PM Superfit, DSLET failed to stimulate GTPase. 
111 















Fig. 4. Multiple components of the stimulation of GTPase by etorphine. Cerebral membranes were treated 
with either 100 PM Superfit (SF) or 2OOpM fi-funaltrexamine (B-FNA) or both, as described under 
Methods. If treated with both alkylators, the membranes were first incubated with Superfit, washed and 
then treated with P-FNA. Subsequently, the activity of GTPase was determined: shown are mean values 
for Ks (open bars) and S,,,,, (closed bars) obtained in 3 experiments carried out in triplicate. Statistical 
significance (see Methods): mean KS values differed from control for the SF and SF + FNA treatments; 
mean S,,, values differed from control for the SF c FNA treatment. 
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described selectivity of the stimulation of GTPase 
complements the resolution of ligand binding to 
multiple opioid receptors, described previously on the 
basis of selective opiates (Gillan and Kosterlitz, 
1982), responses to sodium (Medzihradsky et al., 
1984) and site-directed alkylation using 
/I-chlornaltrexamine (James and Goldstein, 1984). In 
the present work, both methods of alkylation pro- 
vided high selectivity to receptor-effecter coupling, 
i.e. abolished the stimulation of GTPase by ligands of 
the blocked receptors. However, in contrast to the 
protective approach, direct alkylation generally in- 
creased the KS values of the ligands binding to the 
receptor to which specificity was conveyed. The in- 
creased potency of bremazocine in membranes al- 
kylated with p-funaltrexamine apparently reflected 
the elimination of the antagonistic component of this 
opiate at the mu receptor (Von Voigtlander, Lahti 
and Ludens, 1983). It is important to note, that the 
alkylations did not affect the basal rate of the activity 
of GTPase, and in particular, did not increase it. The 
approach described here of opioid receptor al- 
kylations yields membranes from brain suitable for 
the investigation of the selectivity of novel opiates in 
receptor binding and receptor-effecter coupling 
(Medzihradsky, 1987). 
The efficiency of the alkylations was also reflected 
in the quantitative relationships of reoeptor-effector 
coupling: the multiple components of the stimulation 
of GTPase, resulting from the occupancy by etor- 
phine of the mu, kappa and delta opioid receptor, 
respectively, were additive and their sum equalled the 
total enhancement of enzyme activity determined in 
unalkylated membranes. In addition, the extent of the 
stimulation of the enzyme was proportional to the 
degree of alkylation, although the lack of effect on the 
activity of GTPase after alkylation with 10 PM 
Superfit suggests the presence of spare receptors, as 
demonstrated recently in cerebral membranes of the 
rat (Clark and Medzihradsky, 1986). Such a reserve 
has previously been shown also to exist in the cou- 
pling of the opioid receptor to adenylate cyclase in 
NGl08-15 neuroblastoma x glioma hybrid cells 
(Law, Horn and Loh, 1983). 
The described interactions of multiple opioid 
receptors with an effector component in the 
mammalian brain, conveniently determined by its 
enzymatic activity, provide an additional basis for 
assessing the consequences of ligand binding to recep- 
tor. The present authors have studied the efficacy 
of opiate binding with the focus on GTP binding 
proteins (Clark and Medzihradsky, 1986) and are 
now investigating the relationship between the stimu- 
lation of GTPase and the inhibition of adenylate 
cyclase. On the other hand, the present data do not 
yet conclusively identify the GTP-binding protein(s) 
involved in the observed receptor-related stimulation 
of GTPase. However, the recent availability of speci- 
fic antibodies to Ni and No, the latter a pertussis 
toxin sensitive quanine nucleotide-binding protein 
N.P. 26,12--G 
present at large concentrations in brain (Gierschik, 
Milligan, Pines, Goldsmith, Codina, Klee and 
Spiegel, 1986), should prove useful in resolving their 
participation in the phenomena described. 
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